P053: The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)

• Ioanna Xagoraris,
• Konstantina Stathopoulou,
• Persa Xyderou,
• Marzia Palma,
• Elias Drakos,
• Theodoros P. Vassilakopoulos,
• Georgios Z. Rassidakis

Affiliations

Ioanna Xagoraris

1 Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

Konstantina Stathopoulou

1 Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

Persa Xyderou

1 Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

Marzia Palma

1 Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

Elias Drakos

2 Department of Pathology, University of Crete Medical School, Heraklion Crete, Greece

Theodoros P. Vassilakopoulos

3 Department of Haematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece

Georgios Z. Rassidakis

1 Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden